T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections

Antiviral Research

Volumn 82, Issue 3, 2009, Pages 95-102

  Furuta, Yousuke ^a   Takahashi, Kazumi ^a   Shiraki, Kimiyasu ^b   Sakamoto, Kenichi ^c   Smee, Donald F ^d   Barnard, Dale L ^d   Gowen, Brian B ^d   Julander, Justin G ^d   Morrey, John D ^d  

^a TOYAMA CHEMICAL CO LTD   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^d UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral compound; Arenavirus; Bunyavirus; Foot and mouth disease virus; Influenza virus; Pyrazinecarboxamide derivatives; RNA viruses; RNA dependent RNA polymerase; T 705; West Nile virus; Yellow fever virus

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; DNA; FAVIPIRAVIR; INOSINATE DEHYDROGENASE; OSELTAMIVIR; PYRAZINE DERIVATIVE; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; T 1105; T 1106; T 705; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARENAVIRUS; BIOLOGICAL WARFARE; CYTOTOXICITY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; LOADING DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SYNTHESIS; RNA VIRUS INFECTION; TREATMENT OUTCOME; VIRUS CELL INTERACTION; VIRUS RESISTANCE; WEST NILE FLAVIVIRUS; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; NUCLEOSIDES; PYRAZINES; RNA REPLICASE; RNA VIRUS INFECTIONS; RNA VIRUSES; VIRAL PROTEINS;

ANIMALIA; ARENAVIRUS; FOOT-AND-MOUTH DISEASE VIRUS; MAMMALIA; ORTHOBUNYAVIRUS; ORTHOMYXOVIRIDAE; RNA VIRUSES; WEST NILE VIRUS; YELLOW FEVER VIRUS;

EID: 64749093901     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.02.198     Document Type: Review

References (40)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., Naghdaliyev A., Peiris J.S., Shindo N., Soeroso S., and Uyeki T.M. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358 (2008) 261-273
2. Allen L.B., Boswell K.H., Khwaja T.A., Meyer Jr. R.B., Sidwell R.W., Witkowski J.T., Christensen L.F., and Robins R.K. Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin). J. Med. Chem. 21 (1978) 742-746
3. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen Jr. E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., and Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287 (2002) 2391-2405
4. Bray M. Highly pathogenic RNA viral infections: challenges for antiviral research. Antiviral Res. 78 (2008) 1-8
5. Day C.W., Smee D.F., Julander J.G., Yamshchikov V.F., Sidwell R.W., and Morrey J.D. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res. 67 (2005) 38-45
6. Doel T.R. Natural and vaccine-induced immunity to foot-and-mouth disease: the prospects for improved vaccine. O. I. E. Bull. 15 (1996) 883-911
7. Dunn C.S., and Donaldson A.I. Natural adoption to pigs of a Taiwanese isolate of foot-and-mouth disease virus. Vet. Rec. 141 (1997) 174-175
8. Enria D.A., and Maiztegui J.I. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 23 (1994) 23-31
9. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res. 78 (2008) 125-131
10. Ergonul O., Celikbas A., Dokuzoguz B., Eren S., Baykam N., and Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin. Infect. Dis. 39 (2004) 284-287
11. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., Watanabe Y., Narita H., and Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46 (2002) 977-981
12. Furuta Y., Takahashi K., Maekawa M., Maegawa H., Egawa H., and Terashima N. T-1106, a novel pyrazine nucleoside, hepatitis C virus polymerase inhibitor. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. (2004) 199-200 (Abstr. F-487)
13. Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H., and Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49 (2005) 981-986
14. Gibbens J.C., Sharpe C.E., Wilesmith J.W., Mansley L.M., Michalopoulou E., Ryan J.B., and Hudson M. Descriptive epidemiology of the 2001 foot-and-mouth disease epidemic in Great Britain: the first five months. Vet. Rec. 149 (2001) 729-743
15. Glezen W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol. Rev. 4 (1982) 25-44
16. Gowen B.B., and Holbrook M.R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res. 78 (2008) 79-90
17. Gowen B.B., Smee D.F., Wong M.H., Hall J.O., Jung K.H., Bailey K.W., Stevens J.R., Furuta Y., and Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 3 (2008) e3725
18. Gowen B.B., Smee D.F., Wong M.H., Judge J.W., Jung K.H., Bailey K.W., Pace A.M., Rosenberg B., and Sidwell R.W. Recombinant Eimeria protozoan protein elicits resistance to acute phlebovirus infection in mice but not hamsters. Antimicrob. Agents Chemother. 50 (2006) 2023-2029
19. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mendenhall M., Bailey K.W., Furuta Y., and Sidwell R.W. In vitro and in vivo activities of T-705 against Arenavirus and Bunyavirus infections. Antimicrob. Agents Chemother. 51 (2007) 3168-3176
20. Grubman M.J., and Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 17 (2004) 465-493
21. Hayes C.G. West Nile virus: Uganda, 1937 to New York City, 1999. Ann. N. Y. Acad. Sci. 951 (2001) 25-37
22. Heeney J.L. Zoonotic viral diseases and the frontier of early diagnosis, control and prevention. J. Intern. Med. 260 (2006) 399-408
23. Julander J.G., Furuta Y., Shafer K., and Sidwell R.W. Activity of T-1106 in a hamster model of yellow fever virus infection. Antimicrob Agents Chemother. 51 (2007) 1962-1966
24. Julander J.G., Shafer K., Smee D.F., Morrey J.D., and Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with a chemically related compound T-1106. Antimicrob. Agents Chemother. 53 (2009) 202-209
25. Kaye D., and Pringle C.R. Avian influenza viruses and their implication for human health. Clin. Infect. Dis. 40 (2005) 108-112
26. Kilgore P.E., Ksiazek T.G., Rollin P.E., Mills J.N., Villagra M.R., Montenegro M.J., Costales M.A., Paredes L.C., and Peters C.J. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin. Infect. Dis. 24 (1997) 718-722
27. Leyssen P., De Clercq E., and Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 69 (2006) 1461-1467
28. Mardani M., Jahromi M.K., Naieni K.H., and Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin. Infect. Dis. 36 (2003) 1613-1618
29. Markland W., McQuaid T.J., Jain J., and Kwong A.D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44 (2000) 859-866
30. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., and Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314 (1986) 20-26
31. Monath T.P. Treatment of yellow fever. Antiviral Res. 78 (2008) 116-124
32. Morrey J.D., Taro B.S., Siddharthan V., Wang H., Smee D.F., Christensen A.J., and Furuta Y. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 80 (2008) 377-379
33. Plotkin S.A. Vaccines: past, present and future. Nat. Med. 11 (2005) S5-S11
34. Sakamoto K., Ohashi S., Yamazoe R., Takahashi K., and Furuta Y. The inhibition of FMD virus excretion from the infected pigs by an antiviral agent, T-1105. FAO Report of the Research Group of the Standing Technical Committee of European Commission for the control of Foot-and-Mouth Disease, Paphos, Cyprus. FAO Appendix 64 (2006) 418-424
35. Sidwell R.W., Barnard D.L., Day C.W., Smee D.F., Bailey K.W., Wong M.H., Morrey J.D., and Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51 (2007) 845-851
36. Takahashi K., Furuta Y., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., and Shiraki K. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother. 14 (2003) 235-241
37. Tapper M.L. Emerging viral diseases and infectious disease risks. Haemophilia 12 Suppl. 1 (2006) 3-7
38. Tomori O. Yellow fever: the recurring plague. Crit. Rev. Clin. Lab. Sci. 41 (2004) 391-427
39. Webby R.J., and Webster R.G. Are we ready for pandemic influenza?. Science 302 (2003) 1519-1522
40. WHO. Epidemic and Pandemic Alert and Response (EPR) (2008). http://www.who.int/csr/disease/avian influenza/country/en/